You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

~ Buy the BOSULIF (bosutinib monohydrate) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR BOSULIF


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for BOSULIF

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02228382 ↗ Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors Terminated Developmental Therapeutics Consortium Phase 4 2014-11-07 The purpose of this study is to fulfill the post-authorization commitment made by Pfizer to the European Medicines Agency in providing additional safety and efficacy data in approximately 150 Philadelphia Chromosome Positive Chronic Myeloid Leukemia patients with high unmet medical need, including 75 Chronic Phase, Accelerated Phase or Blast Phase patients in the fourth or later line treatment setting (i.e., after treatment with at least 3 other Tyrosine Kinase Inhibitors).
NCT02228382 ↗ Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors Terminated Pfizer Phase 4 2014-11-07 The purpose of this study is to fulfill the post-authorization commitment made by Pfizer to the European Medicines Agency in providing additional safety and efficacy data in approximately 150 Philadelphia Chromosome Positive Chronic Myeloid Leukemia patients with high unmet medical need, including 75 Chronic Phase, Accelerated Phase or Blast Phase patients in the fourth or later line treatment setting (i.e., after treatment with at least 3 other Tyrosine Kinase Inhibitors).
NCT02269267 ↗ The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study) Completed Barbara Ann Karmanos Cancer Institute Phase 2 2014-12-18 This is a non-randomized, prospective, single-group longitudinal study. The purpose of this study is to improve the decision making process used by physicians and patients when they are considering stopping their Tyrosine Kinase Inhibitor (TKI) medication.
NCT02269267 ↗ The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study) Completed Dana-Farber Cancer Institute Phase 2 2014-12-18 This is a non-randomized, prospective, single-group longitudinal study. The purpose of this study is to improve the decision making process used by physicians and patients when they are considering stopping their Tyrosine Kinase Inhibitor (TKI) medication.
NCT02269267 ↗ The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study) Completed Duke Cancer Institute Phase 2 2014-12-18 This is a non-randomized, prospective, single-group longitudinal study. The purpose of this study is to improve the decision making process used by physicians and patients when they are considering stopping their Tyrosine Kinase Inhibitor (TKI) medication.
NCT02269267 ↗ The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study) Completed Emory University Phase 2 2014-12-18 This is a non-randomized, prospective, single-group longitudinal study. The purpose of this study is to improve the decision making process used by physicians and patients when they are considering stopping their Tyrosine Kinase Inhibitor (TKI) medication.
NCT02269267 ↗ The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study) Completed Fred Hutchinson Cancer Center Phase 2 2014-12-18 This is a non-randomized, prospective, single-group longitudinal study. The purpose of this study is to improve the decision making process used by physicians and patients when they are considering stopping their Tyrosine Kinase Inhibitor (TKI) medication.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for BOSULIF

Condition Name

Condition Name for BOSULIF
Intervention Trials
Leukemia 3
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive 2
Chronic Myelogenous Leukemia 2
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for BOSULIF
Intervention Trials
Leukemia, Myeloid 12
Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11
Leukemia 9
Leukemia, Myeloid, Chronic-Phase 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for BOSULIF

Trials by Country

Trials by Country for BOSULIF
Location Trials
United States 90
Italy 11
Spain 4
Austria 2
United Kingdom 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for BOSULIF
Location Trials
Texas 7
California 6
Florida 4
Washington 4
Michigan 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for BOSULIF

Clinical Trial Phase

Clinical Trial Phase for BOSULIF
Clinical Trial Phase Trials
Phase 4 1
Phase 2 7
Phase 1/Phase 2 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for BOSULIF
Clinical Trial Phase Trials
Recruiting 7
Completed 3
Terminated 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for BOSULIF

Sponsor Name

Sponsor Name for BOSULIF
Sponsor Trials
Pfizer 10
National Cancer Institute (NCI) 5
M.D. Anderson Cancer Center 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for BOSULIF
Sponsor Trials
Other 28
Industry 19
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.